A Study of NINLARO® in Chinese Adults With Multiple Myeloma
NCT05013190 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 72
Last updated 2026-01-08
Summary
The main aim of this study is to check side effects and results in adults with multiple myeloma after switching from a bortezomib/carfilzomib -based to an Ixazomib-based treatment.
Conditions
Interventions
- OTHER
-
No intervention
This is a non-interventional study.
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Study Director · Takeda
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-10-29
- Primary Completion
- 2026-12-31
- Completion
- 2026-12-31
- FDA Drug
- Yes
Countries
- China
Study Locations
More Related Trials
-
Conversion to Carfilzomib Therapy in Bortezomib Intolerant Newly Diagnosed Multiple Myeloma(NDMM) Patients
NCT06682156 ·Status: RECRUITING
-
Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)
NCT03748953 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma
NCT00932698 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Real-World Use of Ixazomib Citrate in People With Multiple Myeloma (MM)
NCT04840680 ·Status: COMPLETED
-
A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy
NCT03416374 ·Status: COMPLETED ·Phase: PHASE4
-
Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma
NCT01593410 ·Status: COMPLETED ·Phase: PHASE2
-
This is an Open-label, Single Arm Study to Evaluate the Safety and Tolerability of Treatment With CT0591CP in Patients With Relapsed and/or Refractory Multiple Myeloma.
NCT05486975 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Quality of Life, Symptoms and Treatment Satisfaction in Adult Patients With Relapsed and/or Refractory Multiple Myeloma, Receiving Ixazomib (Ninlaro®) in Combination With Lenalidomide and Dexamethasone in a Real World Setting: Pilot Study
NCT03903406 ·Status: UNKNOWN
-
Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse
NCT01217203 ·Status: COMPLETED ·Phase: PHASE1
-
Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral IXAZOMIB in Adult Patients With Relapsed and Refractory Multiple Myeloma
NCT00963820 ·Status: COMPLETED ·Phase: PHASE1
-
Phase 1 Pharmacokinetic Study of Oral Ixazomib Plus Lenalidomide and Dexamethasone in Adult Asian Participants With Relapsed and/or Refractory Multiple Myeloma
NCT01645930 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant
NCT02181413 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of VRd-based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With New-diagnosed Multiple Myeloma
NCT05860036 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study in Relapsed and/or Refractory Multiple Myeloma Patients Treated With Ixazomib Plus Lenalidomide and Dexamethasone
NCT03433001 ·Status: COMPLETED
-
Efficacy and Safety of Zoledronic Acid in Patients With Bone Metastases of Any Solid Tumors or Multiple Myeloma
NCT00219258 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Participants With Relapsed and/or Refractory Multiple Myeloma
NCT02917941 ·Status: COMPLETED ·Phase: PHASE2
-
Id and Rd Maintenance Regimens After Induction of Remission in Multiple Myeloma.
NCT05477797 ·Status: RECRUITING ·Phase: NA
-
Study of Pomalidomide, Oral Dexamethasone and Ixazomib in Patients With Relapsed MM Who Have Received Lenalidomide
NCT04989140 ·Status: UNKNOWN ·Phase: PHASE4
-
S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma
NCT01668719 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Mitoxantrone Hydrochloride Liposome Combination Regimen in the Treatment of High-risk/Extramedullary Multiple Myeloma
NCT06246162 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Modified Bortezomib-based Combination Therapy for Multiple Myeloma
NCT02559154 ·Status: UNKNOWN ·Phase: PHASE4
-
A Phase 2 Study of Lenalidomide to Evaluate the Efficacy in Japanese Patients With Newly Diagnosed Multiple Myeloma
NCT01698801 ·Status: COMPLETED ·Phase: PHASE2
-
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Participants With Normal Renal Function or Severe Renal Impairment
NCT01830816 ·Status: COMPLETED ·Phase: PHASE1
-
Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma
NCT06517017 ·Status: RECRUITING ·Phase: PHASE2
-
Evaluation of Activity, Safety and Pharmacology of IPH2101 a Human Monoclonal Antibody in Patients With Multiple Myeloma
NCT00999830 ·Status: COMPLETED ·Phase: PHASE2